Cephalon

TFF Pharmaceuticals Appoints Thomas B. King to Board of Directors

Retrieved on: 
Wednesday, December 13, 2023
McPherson College, Business, Marketing, Chemistry, MAA, NDA, MBA, Bachelor of Arts, Cephalon, University, Abbott Laboratories, Laboratory, IPO, Patient, TFF, Management

King to its Board of Directors.

Key Points: 
  • King to its Board of Directors.
  • “I am pleased to welcome Thomas King to our Board of Directors,” said Harlan Weisman, M.D., Vice Chairman and Chief Executive Officer of TFF Pharmaceuticals.
  • “Tom is an exceptionally accomplished executive who has held leadership positions at life sciences companies over the last three decades.
  • Presently, Mr. King sits on the board of several companies, including Achieve Life Sciences (Nasdaq: ACHV), Kinaset Therapeutics, and Concentric Analgesics.

OtoNexus Medical Technologies Welcomes Chris Rivera to its Board of Directors

Retrieved on: 
Tuesday, April 4, 2023
Genzyme, IPO, Acquisition, National Council, Growth, FDA, Therapy, Tercica, Horizon Therapeutics, Management, Cephalon

SEATTLE, April 4, 2023 /PRNewswire/ -- OtoNexus Medical Technologies, Inc. is pleased to announce the appointment of Chris Rivera to its Board of Directors.

Key Points: 
  • SEATTLE, April 4, 2023 /PRNewswire/ -- OtoNexus Medical Technologies, Inc. is pleased to announce the appointment of Chris Rivera to its Board of Directors.
  • Mr. Rivera has a demonstrated track record of success in building and exiting life sciences companies throughout his career.
  • "I am excited to join the OtoNexus Board of Directors and work with the team to advance its innovative technology," said Chris.
  • The addition of Chris Rivera to the OtoNexus Board of Directors further strengthens the company's leadership and positions it for success in the life sciences industry.

Matthew Shaulis appointed Chief Commercial Officer and US President of Hansa Biopharma

Retrieved on: 
Friday, March 3, 2023
Schering-Plough, Hansa, Popular Executive Committee of Valencia, Immunology, Teva, Senior, Acquisition, Executive Committee, Inflammation, Johnson & Johnson, Management, Pfizer, Cephalon

LUND, Sweden, March 3, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (NASDAQ Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, announced today that Matthew Shaulis will join the company effective 16 March as Chief Commercial Officer and President of the U.S. affiliate, Hansa Biopharma, Inc.

Key Points: 
  • LUND, Sweden, March 3, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (NASDAQ Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, announced today that Matthew Shaulis will join the company effective 16 March as Chief Commercial Officer and President of the U.S. affiliate, Hansa Biopharma, Inc.
  • He will report to President and CEO Søren Tulstrup and join the Executive Committee.
  • I would like to thank and congratulate Henk Doude van Troostwijk, who is moving into a new role as Vice President, Commercial Excellence, for his many contributions."
  • I'm looking forward to partnering across the enterprise to build out the U.S. organization and advance the global commercial priorities."

LAVA Therapeutics Announces the Appointment of Dr. Charles Morris as Chief Medical Officer

Retrieved on: 
Monday, February 6, 2023
Pharmacology, Breast cancer, Lymphoma, Royal college, Bachelor of Medicine, Bachelor of Surgery, Cancer, CAR, Fulvestrant, LAVA, ImmunoGen, Patient, Bachelor, Cephalon, Physician, AstraZeneca, Research, Doctor of Philosophy, Therapy, Pharmaceutical industry, MD, Medicine

“During a 25-year tenure in the industry, Dr. Morris has demonstrated a proven track record of advancing novel oncology product candidates from clinical development through global regulatory approvals,” said Stephen Hurly, president and chief executive officer of LAVA Therapeutics.

Key Points: 
  • “During a 25-year tenure in the industry, Dr. Morris has demonstrated a proven track record of advancing novel oncology product candidates from clinical development through global regulatory approvals,” said Stephen Hurly, president and chief executive officer of LAVA Therapeutics.
  • Dr. Morris is a medical oncologist with over 25 years of oncology drug development experience working with global biotech and pharmaceutical companies and managing numerous drug approvals.
  • Most recently, he was the chief medical officer for Celyad Oncology, a biotechnology company focused on the research and discovery of chimeric antigen receptor T cell (CAR T) therapies for cancer.
  • Dr. Morris also served as chief medical officer of Radius Health and held leadership positions at PsiOxus Therapeutics, ImmunoGen and Allos Therapeutics, where he contributed to all phases of development for solid and hematological tumor indications.

Novavax Names John C. Jacobs as New President & Chief Executive Officer

Retrieved on: 
Monday, January 9, 2023
IPO, NVAX, Partnership, State University of New York College of Environmental Science and Forestry, State University of New York, COVID-19, Wyeth, Commercial Operating System (COS), Teva Pharmaceuticals, Infection, World Health Organization, State university system, Health, FDA, Harmony, Cephalon, Vaccine, Senior, Doctor of Philosophy, Management, Pharmaceutical industry, Pfizer, Novavax, Teva

"Stan led Novavax from a clinical development organization to a global commercial vaccines company during a worldwide pandemic.

Key Points: 
  • "Stan led Novavax from a clinical development organization to a global commercial vaccines company during a worldwide pandemic.
  • This foundation puts Novavax in a strong position to execute on its long-term strategy, and we look forward to supporting Stan and John through the transition.
  • John is a seasoned industry leader who will bring a fresh perspective and deep industry expertise to Novavax."
  • He will join Novavax from Harmony Biosciences, where he has served as President and Chief Executive Officer and a member of the Board of Directors since June 2018, and Executive Vice President and Chief Commercial Officer from October 2017 to June 2018.

Blue Foundry Bancorp Names Elizabeth Varki Jobes, Esq. to Board of Directors

Retrieved on: 
Thursday, January 5, 2023
Auxilium, Therapy, Spark Therapeutics, Merck Serono, Rutgers Law School, Law, Blue, Senior, Management, Cephalon

RUTHERFORD, N.J., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Blue Foundry Bancorp (Nasdaq: BLFY) (the “Company”), announced today the appointment of Elizabeth Varki Jobes, Esq.

Key Points: 
  • RUTHERFORD, N.J., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Blue Foundry Bancorp (Nasdaq: BLFY) (the “Company”), announced today the appointment of Elizabeth Varki Jobes, Esq.
  • James D. Nesci, President and Chief Executive Officer stated, “We are excited to welcome Ms. Jobes to Blue Foundry’s Board of Directors.
  • She currently serves on the board of Ampio Pharmaceuticals, a public company, as well as the board of a private biopharmaceutical company (Eyam Vaccines and Immunotherapeutics), and the board of a not-for-profit organization.
  • Ms. Jobes is a member of the South Asian Bar Association and was a former board member of Women’s Way.

Minovia Therapeutics appoints Maha Radhakrishnan, Chief Medical Officer at Biogen, as board member

Retrieved on: 
Thursday, January 5, 2023
Partnership, GMP, Central nervous system, Degenerative disease, Therapy, Cardiology, Drug development, Research, UnitedHealth Group, Pearson syndrome, MAT, Patient, Bristol Myers Squibb, Ophthalmology, Astellas Pharma, Neurology, Safety, Entrepreneurship, Science Translational Medicine, Rheumatology, Internal medicine, Diabetes, Psychiatry, Pharmaceutical industry, Biogen, Cephalon

TIRAT HACARMEL, Israel, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Minovia Therapeutics (Minovia) , a clinical-stage company focused on developing novel Mitochondrial Augmentation Technology (MAT) to fight mitochondrial diseases, has announced a Board appointment.

Key Points: 
  • TIRAT HACARMEL, Israel, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Minovia Therapeutics (Minovia) , a clinical-stage company focused on developing novel Mitochondrial Augmentation Technology (MAT) to fight mitochondrial diseases, has announced a Board appointment.
  • Maha Radhakrishnan, M.D., joins the board at a time in which the company advances clinical programs in primary mitochondrial diseases and hematological disorders associated with mitochondrial dysfunction.
  • As a trained physician, Maha is a senior leader with extensive pharmaceutical and biotech experience covering clinical development, post-marketing regulatory activities, medical affairs, safety, and reimbursement requirements.
  • Maha is the Chief Medical Officer of Biogen, and in her previous roles, she served as Senior Vice President and Global Head of Medical, Primary Care Business Unit at Sanofi, Senior Vice President and Head of Worldwide Medical at Bioverativ Therapeutics Inc., and Head of Europe & Canada Medical and US Medical at Biogen.

Annovis Bio Announces New Appointments to Strengthen Its Senior Leadership Team

Retrieved on: 
Friday, January 6, 2023
Parkinson's disease, Gian Maria Annovi, Toxicology, Chemical process, Laboratory, Pilot plant, Disease, Alzheimer's disease, Forest Products Laboratory, Research, NYSE, Teva Pharmaceuticals, Regulatory Toxicology and Pharmacology, FDA, Cephalon, Process, Neurodegeneration, Pharmaceutical industry, Pharmacology

BERWYN, Penn., Jan. 6, 2023 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced key additions to its senior leadership team with the appointments of Dr. Michael Christie as Vice President of Process Chemistry and David Prohaska as Vice President of Toxicology and Pharmacology.

Key Points: 
  • BERWYN, Penn., Jan. 6, 2023 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced key additions to its senior leadership team with the appointments of Dr. Michael Christie as Vice President of Process Chemistry and David Prohaska as Vice President of Toxicology and Pharmacology.
  • Maria L. Maccecchini, Ph.D., Founder, President, and CEO of Annovis commented, "The expertise of Dr. Michael Christie and David Prohaska will significantly strengthen our ability to conduct successful clinical trials and navigate the regulatory process.
  • Michael Christie, Ph.D., brings to Annovis over 40 years of experience in the pharmaceutical industry.
  • Mr. Prohaska joins Annovis from Aravive Biologics where he served as the Director of Preclinical Development and Clinical Operations Support.

PhRMA Foundation Announces New Members of Board of Directors

Retrieved on: 
Tuesday, November 29, 2022
UnitedHealth Group, Doctor of Philosophy, Pharmaceutical Research and Manufacturers of America, Medical school, Environment, Merck & Co., United States House Ways and Means Subcommittee on Health, Multimedia, Novartis, Bristol Myers Squibb, Physician, Policy, Patient, California Institute for Quantitative Biosciences, Research, Ways and means committee, Senior, Cancer, School, Translational medicine, Biogen, Commerce, Drug discovery, Stanford University School of Medicine, House Committee, Stanford University, Pharmaceutical industry, Management, Sanofi, Merck, MD, Cephalon, Medicine, Pfizer

The PhRMA Foundation is a 57-year-old nonprofit that fosters biopharmaceutical innovation and value-driven health care by investing in the frontiers of research.

Key Points: 
  • The PhRMA Foundation is a 57-year-old nonprofit that fosters biopharmaceutical innovation and value-driven health care by investing in the frontiers of research.
  • "These new Board members bring to the PhRMA Foundation a diversity of experience and perspective that is critical as we enter the next era of change for the biopharmaceutical industry," said Amy M. Miller, PhD, President of the PhRMA Foundation.
  • "I look forward to working with our Board of Directors to chart a path forward for the organization and support the rapidly evolving field."
  • "I look forward to working with my fellow Board members at the PhRMA Foundation to foster innovative research and inspire a new and diverse generation of biopharmaceutical scientists."

CARsgen Appoints Dr. Sylvie Peltier as Senior Vice President of Global Regulatory Affairs

Retrieved on: 
Monday, October 31, 2022
Health law, View, Multimedia, CMC, Therapy, Regulatory affairs, Knowledge, Diploma in Pharmacy, Patient, TEVA, DESS, Cancer, NYSE, Company, Paris-Sud University, Doctor of Pharmacy, University, NASDAQ, Senior, File, CAR, Cephalon, Head, Medical device, Pharmaceutical industry

Dr. Peltier has extensive global leadership and hands-on experiences in clinical and CMC regulatory affairs across several multinational pharmaceutical and biopharmaceutical companies.

Key Points: 
  • Dr. Peltier has extensive global leadership and hands-on experiences in clinical and CMC regulatory affairs across several multinational pharmaceutical and biopharmaceutical companies.
  • Prior to joining CARsgen, Dr. Peltier served as Vice President, Head of US Regulatory Affairs at MorphoSys US Inc (NASDAQ: MOR) since 2020, and as Head of Regulatory Affairs at Servier Pharmaceuticals LLC from 2018.
  • Dr. Raffaele Baffa, Chief Medical Officer of CARsgen Therapeutics, said: "We are delighted to have Dr. Peltier join CARsgen.
  • Dr. Sylvie Peltier, Senior Vice President of Global Regulatory Affairs of CARsgen Therapeutics, said: "CARsgen is a leader in CAR T-cell therapies globally, with competitive product pipelines and technology platforms.